Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
CONCLUSIONS: Switching to insulin degludec from other basal insulins can improve glycaemic control and/or reduce hypoglycaemia risk in people with diabetes (although there was a nonsignificant reduction in HbA1c and hypoglycaemia rates for the neutral protamine Hagedorn group in Type 1 diabetes) under routine care. This article is protected by copyright. All rights reserved.
PMID: 31001865 [PubMed - as supplied by publisher]
Source: Molecular Medicine - Category: Molecular Biology Authors: Knudsen ST, Lapolla A, Schultes B, Tentolouris N, Catarig AM, Wolden ML, Siegmund T Tags: Diabet Med Source Type: research
More News: Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Insulin | Lantus | Levemir | Molecular Biology | Statistics | Study